rss
05-27-2015, 09:17 PM
Mela**ma Therapeutics Market Research Report to 2020 – Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth
The Report Mela**ma Therapeutics Market (http://www.marketresearchreports.biz/analysis/228608) to 2020 – Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz
GBI Research, a leading business intelligence provider, has released its latest research report “Mela**ma Therapeutics Market to 2020 – Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth.”
Mela**ma is a highly heterogeneous disease comprising Cutaneous Mela**ma (CM), Ocular Mela**ma (OM), Mucosal Mela**ma (MM), mela**ma of the internal organs, and, according to some classifications, mela**ma of the soft parts (**n-bony and **n-cartilagi**us tissues) of the body. CM is by far the most common form of mela**ma, accounting for approximately 90–95% of all mela**mas.
View Full Report at http://www.marketresearchreports.biz/analysis/228608
Historically, mela**ma has been considered as a very challenging disease to treat with pharmacotherapy. However, in recent years, understanding of the pathophysiology and heterogeneity of mela**ma, and particularly CM, has developed considerably. This has led to the approval of several new drug agents indicated for CM since 2011, namely Sylatron (peginterferon alfa-2b), Yervoy (ipilimumab), Opdivo, (nivolumab), Keytruda (pembrolizumab), Zelboraf (vemurafenib), Tafinlar (dabrafenib) and Mekinist (trametinib). These ***** have dramatically improved the treatment options for CM patients, leading to unprecedented market growth.
Rapid market growth is also anticipated over the forecast period due to the expanding mela**ma treatment population and the continued uptake of recently approved *****. The mela**ma pipeline is currently strong, with several promising molecules in development including, Poly**ma’s seviprotimut-L, Amgen’s talimogene laherparepvec (T-VEC) and Roche and Genentech’s cobimetinib in combination with Zelboraf, which are in development for CM, as well as AstraZeneca’s selumetinib which is in development for OM. Consequently, the mela**ma therapeutics market is projected to grow from $1.3 billion in 2013 to $3.6 billion in 2020, at a CAGR of 15.4%.
Download Sample Copy of this Report at http://www.marketresearchreports.biz/sample/sample/228608
Scope
The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts across indications for mela**ma.
The report covers and includes:
An introduction to the mela**ma indication, including disease symptoms, epidemiology, etiology, pathophysiology, staging, diag**sis and treatment.
In-depth analysis of the current mela**ma marketed products landscape including product profiles of the main ***** used in mela**ma and heat maps that compare safety and efficacy parameters of the various *****.
Comprehensive analysis of the mela**ma pipeline by phase of development, molecule type, molecular target and **velty. A comparative analysis of late-stage pipeline ***** that are likely to enter the market in the forecast period is also provided alongside heat maps.
Additional in-depth analysis of mela**ma clinical trials by size, duration, failure rates and primary and secondary endpoints.
Multi-scenario forecast data for the market to 2020, taking into account how it will be affected by the introduction of new ***** and changes in disease epidemiology across the key developed markets, the US, Canada, the UK, France, Germany, Italy, Spain and Japan.
Discussion of the licensing and co-development strategic consolidations landscape in mela**ma, by Phase of development and molecule type, as well as an analysis of both licensing and co-development deals by year, and network maps of licensing and co-development deals.
Reasons To Buy
The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to:
Gain a comprehensive understanding of the mela**ma indication including segmentation of disease and treatment algorithms.
Understand the current mela**ma marketed products landscape and recognize the dominant therapeutic agents and pharmaceutical players involved.
Identify trends and developments within the mela**ma pipeline including which molecule types and molecular targets are prominent.
Consider market opportunities and potential risks by examining trends in mela**ma clinical trial duration and size, as well as clinical trial failure rates, amongst clinical trial Phases and molecule types.
Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the mela**ma therapeutics market.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Introduction
2.2 Types of Mela**ma
2.3 Symptoms
2.3.1 Cutaneous Mela**ma
2.3.2 Ocular Mela**ma
2.3.3 Mucosal Mela**mas
2.3.4 Mela**mas of the Internal Organs and Soft Parts
2.3.5 Advanced Mela**ma
2.4 Etiology and Risk Factors
2.4.1 Phe**typic Characteristics
2.4.2 Exposure to Ultraviolet Radiation
2.4.3 Personal or Family History of Mela**ma
2.4.4 Xeroderma Pigmentosum
2.4.5 Parkinson’s Disease
2.5 Pathophysiology
2.5.1 Cutaneous Mela**ma
2.5.2 Ocular Mela**ma
2.5.3 Mucosal Mela**ma
2.5.4 Underlying Molecular Pathways
2.6 Mela**ma Staging
2.7 Diag**sis
2.7.1 Cutaneous Mela**ma
2.7.2 Ocular Mela**ma
2.7.3 Mucosal Mela**ma
2.8 Epidemiology
2.8.1 Cutaneous Mela**ma
2.8.2 Ocular Mela**ma
2.8.3 Mucosal Mela**ma
2.9 Treatment Options
About Us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Read our latest articles at http://www.marketresearchreports.biz/articles
Contact* Us
******: State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: [email protected]
The post Mela**ma Therapeutics Market Research Report to 2020 – Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth (http://www.medgadget.com/2015/05/mela**ma-therapeutics-market-research-report-2020-rising-prevalence-evolving-treatment-algorithms-drive-market-growth.html) appeared first on Medgadget (http://www.medgadget.com).
http://feeds.feedburner.com/~ff/Medgadget?d=yIl2AUoC8zA (http://feeds.feedburner.com/~ff/Medgadget?a=9hOu6b5AvcQ:Ltnq4dEbdRA:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/Medgadget?d=qj6IDK7rITs (http://feeds.feedburner.com/~ff/Medgadget?a=9hOu6b5AvcQ:Ltnq4dEbdRA:qj6IDK7rITs) http://feeds.feedburner.com/~ff/Medgadget?i=9hOu6b5AvcQ:Ltnq4dEbdRA:gIN9vFwOqvQ (http://feeds.feedburner.com/~ff/Medgadget?a=9hOu6b5AvcQ:Ltnq4dEbdRA:gIN9vFwOqvQ)
http://feeds.feedburner.com/~r/Medgadget/~4/9hOu6b5AvcQ
The Report Mela**ma Therapeutics Market (http://www.marketresearchreports.biz/analysis/228608) to 2020 – Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz
GBI Research, a leading business intelligence provider, has released its latest research report “Mela**ma Therapeutics Market to 2020 – Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth.”
Mela**ma is a highly heterogeneous disease comprising Cutaneous Mela**ma (CM), Ocular Mela**ma (OM), Mucosal Mela**ma (MM), mela**ma of the internal organs, and, according to some classifications, mela**ma of the soft parts (**n-bony and **n-cartilagi**us tissues) of the body. CM is by far the most common form of mela**ma, accounting for approximately 90–95% of all mela**mas.
View Full Report at http://www.marketresearchreports.biz/analysis/228608
Historically, mela**ma has been considered as a very challenging disease to treat with pharmacotherapy. However, in recent years, understanding of the pathophysiology and heterogeneity of mela**ma, and particularly CM, has developed considerably. This has led to the approval of several new drug agents indicated for CM since 2011, namely Sylatron (peginterferon alfa-2b), Yervoy (ipilimumab), Opdivo, (nivolumab), Keytruda (pembrolizumab), Zelboraf (vemurafenib), Tafinlar (dabrafenib) and Mekinist (trametinib). These ***** have dramatically improved the treatment options for CM patients, leading to unprecedented market growth.
Rapid market growth is also anticipated over the forecast period due to the expanding mela**ma treatment population and the continued uptake of recently approved *****. The mela**ma pipeline is currently strong, with several promising molecules in development including, Poly**ma’s seviprotimut-L, Amgen’s talimogene laherparepvec (T-VEC) and Roche and Genentech’s cobimetinib in combination with Zelboraf, which are in development for CM, as well as AstraZeneca’s selumetinib which is in development for OM. Consequently, the mela**ma therapeutics market is projected to grow from $1.3 billion in 2013 to $3.6 billion in 2020, at a CAGR of 15.4%.
Download Sample Copy of this Report at http://www.marketresearchreports.biz/sample/sample/228608
Scope
The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts across indications for mela**ma.
The report covers and includes:
An introduction to the mela**ma indication, including disease symptoms, epidemiology, etiology, pathophysiology, staging, diag**sis and treatment.
In-depth analysis of the current mela**ma marketed products landscape including product profiles of the main ***** used in mela**ma and heat maps that compare safety and efficacy parameters of the various *****.
Comprehensive analysis of the mela**ma pipeline by phase of development, molecule type, molecular target and **velty. A comparative analysis of late-stage pipeline ***** that are likely to enter the market in the forecast period is also provided alongside heat maps.
Additional in-depth analysis of mela**ma clinical trials by size, duration, failure rates and primary and secondary endpoints.
Multi-scenario forecast data for the market to 2020, taking into account how it will be affected by the introduction of new ***** and changes in disease epidemiology across the key developed markets, the US, Canada, the UK, France, Germany, Italy, Spain and Japan.
Discussion of the licensing and co-development strategic consolidations landscape in mela**ma, by Phase of development and molecule type, as well as an analysis of both licensing and co-development deals by year, and network maps of licensing and co-development deals.
Reasons To Buy
The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to:
Gain a comprehensive understanding of the mela**ma indication including segmentation of disease and treatment algorithms.
Understand the current mela**ma marketed products landscape and recognize the dominant therapeutic agents and pharmaceutical players involved.
Identify trends and developments within the mela**ma pipeline including which molecule types and molecular targets are prominent.
Consider market opportunities and potential risks by examining trends in mela**ma clinical trial duration and size, as well as clinical trial failure rates, amongst clinical trial Phases and molecule types.
Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the mela**ma therapeutics market.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Introduction
2.2 Types of Mela**ma
2.3 Symptoms
2.3.1 Cutaneous Mela**ma
2.3.2 Ocular Mela**ma
2.3.3 Mucosal Mela**mas
2.3.4 Mela**mas of the Internal Organs and Soft Parts
2.3.5 Advanced Mela**ma
2.4 Etiology and Risk Factors
2.4.1 Phe**typic Characteristics
2.4.2 Exposure to Ultraviolet Radiation
2.4.3 Personal or Family History of Mela**ma
2.4.4 Xeroderma Pigmentosum
2.4.5 Parkinson’s Disease
2.5 Pathophysiology
2.5.1 Cutaneous Mela**ma
2.5.2 Ocular Mela**ma
2.5.3 Mucosal Mela**ma
2.5.4 Underlying Molecular Pathways
2.6 Mela**ma Staging
2.7 Diag**sis
2.7.1 Cutaneous Mela**ma
2.7.2 Ocular Mela**ma
2.7.3 Mucosal Mela**ma
2.8 Epidemiology
2.8.1 Cutaneous Mela**ma
2.8.2 Ocular Mela**ma
2.8.3 Mucosal Mela**ma
2.9 Treatment Options
About Us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Read our latest articles at http://www.marketresearchreports.biz/articles
Contact* Us
******: State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: [email protected]
The post Mela**ma Therapeutics Market Research Report to 2020 – Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth (http://www.medgadget.com/2015/05/mela**ma-therapeutics-market-research-report-2020-rising-prevalence-evolving-treatment-algorithms-drive-market-growth.html) appeared first on Medgadget (http://www.medgadget.com).
http://feeds.feedburner.com/~ff/Medgadget?d=yIl2AUoC8zA (http://feeds.feedburner.com/~ff/Medgadget?a=9hOu6b5AvcQ:Ltnq4dEbdRA:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/Medgadget?d=qj6IDK7rITs (http://feeds.feedburner.com/~ff/Medgadget?a=9hOu6b5AvcQ:Ltnq4dEbdRA:qj6IDK7rITs) http://feeds.feedburner.com/~ff/Medgadget?i=9hOu6b5AvcQ:Ltnq4dEbdRA:gIN9vFwOqvQ (http://feeds.feedburner.com/~ff/Medgadget?a=9hOu6b5AvcQ:Ltnq4dEbdRA:gIN9vFwOqvQ)
http://feeds.feedburner.com/~r/Medgadget/~4/9hOu6b5AvcQ